https://isra.news ответы как позвонить на мобильный в израиль.
This page updated:
1/7/2007 12:49:00 PM
DoctorFungus - All Rights Reserved
© 2007 Copyright
Site built and designed for doctorfungus by Webillustrated
You are here:
> Descriptions >
(described by Matruchot in 1903)
Cunninghamella is a filamentous fungus found in soil and plant material, particularly at Mediterranean and subtropical zones. It has also been recovered from animal material, cheese, and Brazil nuts. In addition to being a common contaminant, Cunninghamella is an opportunistic fungus that may cause infections in immunocompromised hosts [531, 1295, 2144, 2202].
The genus Cunninghamella currently contains seven species. While Cunninghamella bertholletiae, Cunninghamella elegans, and Cunninghamella echinulata are the most common species, Cunninghamella bertholletiae is the only known human and animal pathogen.
The nomenclature for Cunninghamella species is rather complicated. While some authorities accept Cunninghamella bertholletiae, Cunninghamella elegans, and Cunninghamella echinulata as separate species , others tend to use the names Cunninghamella bertholletiae and Cunninghamella echinulata as the synonyms of Cunninghamella elegans . However, the latter approach is not very convincing, since the purely gray color of its colonies and its inability to grow at 45°C clearly differentiates Cunninghamella elegans from Cunninghamella bertholletiae. Thus, we prefer to follow the previous approach and accept the existence of the three species separately in the genus Cunninghamella.
Cunninghamella spp. are among the causative agents of zygomycosis. Although the term mucormycosis has often been used for this syndrome, zygomycosis is now the preferred term for this angio-invasive disease. Trauma, diabetes mellitus, immunosuppression due to various reasons (hematological malignancies, organ transplantation, AIDS), and desferoxamine therapy are the major risk factors for development of zygomycosis. Among the other genera belonging to the class zygomycetes, Cunninghamella is particularly sensitive to desferoxamine therapy. Lastly and importantly, Cunninghamella infections have been reported in a number of cases receiving antifungal prophylaxis with itraconazole .
Cunninghamella bertholletiae may cause rhinocerebral, pulmonary, cutaneoarticular, and disseminated forms of zygomycosis. The infection usually starts after inhalation of the spores or inoculation of the fungus following the primary breakdown of the skin integrity due to a trauma [62, 277, 516, 1474, 1589, 1906, 1918, 1925, 2042].
Cunninghamella colonies are rapidly growing (mature in 4 days), cottony, and white to tannish-gray in color. The reverse is pale. Cunninghamella elegans produces purely gray colonies. While Cunninghamella bertholletiae may grow at temperatures as high as 45°C, Cunninghamella elegans fails to grow at this temperature [531, 1295, 2144, 2202].
Nonseptate or sparsely septate broad hyphae, sporangiophores, terminal vesicles, sporangioles (sporangiola; sing. sporangiolum), and sporangiospores are visualized. Sporangiophores are erect and form short lateral branches each of which terminates in a swollen vesicle. The vesicle (30-65 µm in diameter) has spine-like denticles on its surface. Sporangioles (5-8 x 6-14 µm) are round to oval in shape, one-spored, and are formed on these denticles. Sporangiospores are one-celled, solitary, and globose to ovoid in shape. The walls of the spores often have needle-like crystals. Zygospores have tuberculate projections and may form only after appropriate mating studies [531, 1295, 2144, 2202].
See our histopathology page.
Unlike Cunninghamella, the terminal vesicle on the sporangiophore of Syncephalastrum bears finger-shaped sporangia on its surface. Each of these sporangia is called merosporangium. Each merosporangium carries linearly arranged sporangiospores inside.
No special precautions other than general laboratory precautions are required.
Very few data are available and there is as yet no standard method for in vitro susceptibility testing of Cunninghamella spp. In an in vitro study where two Cunninghamella echinulata strains were tested, the rank of MICs was found to be voriconazole, ketoconazole, amphotericin B, itraconazole .
On the other hand, amphotericin B, ketoconazole, and itraconazole generated considerably high MICs for some isolates of Cunninghamella spp. in other workers' hands .
For MICs of various antifungal drugs for Cunninghamella, see our susceptibility database.
Liposomal amphotericin B has been used for treatment of Cunninghamella infections. However, prognosis is often poor .
Cunninghamella bertholletiae sporangiola
62. Anaissie, E., G. P. Bodey, H. Kantarjian, J. Ro, S. E. Vartivarian, R. Hopfer, J. Hoy, and K. Rolston. 1989. New spectrum of fungal infections in patients with cancer. Rev Infect Dis. 11:369-378.
277. Boelaert, J. R., M. de Locht, and Y.-J. Schneider. 1994. The effect of deferoxamine on different zygomycetes. J. Infect. Dis. 169:231-232.
516. Darrisaw, L., G. Hanson, D. H. Vesole, and S. C. Kehl. 2000. Cunninghamella infection post bone marrow transplant: case report and review of the literature. Bone Marrow Transplant. 25:1213-1216.
531. de Hoog, G. S., J. Guarro, J. Gene, and M. J. Figueras. 2000. Atlas of Clinical Fungi, 2nd ed, vol. 1. Centraalbureau voor Schimmelcultures, Utrecht, The Netherlands.
1295. Larone, D. H. 1995. Medically Important Fungi - A Guide to Identification, 3rd ed. ASM Press, Washington, D.C.
1389. Lunn, J. A., and W. A. Shipton. 1983. Re-evaluation of taxonomic criteria in Cunninghamella. Trans Br Mycol Soc. 81:303-12.
1474. Mazade, M. A., J. F. Margolin, S. N. Rossmann, and M. S. Edwards. 1998. Survival from pulmonary infection with Cunninghamella bertholletiae: case report and review of the literature. Pediat Inf Dis J. 17:835-839.
1589. Mostaza, J. M., F. J. Barbado, J. Fernandez-Martin, J. Pena-Yanez, and J. J. Vazquez-Rodriguez. 1989. Cutaneoarticular mucormycosis due to Cunninghamella bertholletiae in a patient with AIDS. Rev. Infect. Dis. 11:316-318.
1906. Rex, J. H., A. M. Ginsberg, L. F. Fries, H. I. Pass, and K. J. Kwon-Chung. 1988. Cunninghamella bertholletiae infection associated with deferoxamine therapy. Rev. Infect. Dis. 10:1187-1194.
1918. Ribes, J. A., C. L. Vanover-Sams, and D. J. Baker. 2000. Zygomycetes in human disease. Clin Microbiol Rev. 13:236-301.
1925. Rickerts, V., A. Bohme, A. Viertel, G. Behrendt, V. Jacobi, K. Tintelnot, and G. Just-Nubling. 2000. Cluster of pulmonary infections caused by Cunninghamella bertholletiae in immunocompromised patients. Clin Infect Dis. 31:910-913.
1973. Rotowa, N. A., H. J. Shadomy, and S. Shadomy. 1990. In vitro activities of polyene and imidazole antifungal agents against unusual opportunistic fungal pathogens. Mycoses. 33:203-11.
2042. Schell, W. A. 2000. Unusual fungal pathogens in fungal rhinosinusitis. Otolaryngol Clin N Amer. 33:367-373,X.
2144. St-Germain, G., and R. Summerbell. 1996. Identifying Filamentous Fungi - A Clinical Laboratory Handbook, 1st ed. Star Publishing Company, Belmont, California.
2202. Sutton, D. A., A. W. Fothergill, and M. G. Rinaldi (ed.). 1998. Guide to Clinically Significant Fungi, 1st ed. Williams & Wilkins, Baltimore.
2397. Weitzman, I. 1984. The case for Cunninghamella elegans, C. bertholletiae, and C. echinulata as seperate species. Trans Br Mycol Soc. 83:527-8.
2432. Wildfeuer, A., H. P. Seidl, I. Paule, and A. Haberreiter. 1998. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin. Mycoses. 41:309-319.